Enveric Biosciences, Inc. — Q1 2023 Form 10-Q
Business and period: The filing covers the three months ended March 31, 2023. Enveric is a pre-revenue biotechnology company developing psychedelic-derived and cannabinoid therapeutics; management says its principal focus is psychedelic-based treatments. Its pipeline includes EB-373, a preclinical psilocin prodrug for anxiety disorders.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | None reported; the company says it has not generated revenue | None reported |
| Operating expenses | $4.86 million | $4.80 million, up about 1% |
| Operating loss | $4.86 million | $4.80 million |
| Net loss | $4.68 million | $4.52 million |
| Net loss attributable to shareholders | $4.80 million; $2.31 per share | $4.52 million; $5.34 per share |
| Cash used in operations | $5.14 million | $4.55 million |
| Cash at period end | $12.56 million | $21.69 million at March 31, 2022 |
At March 31, 2023, working capital was $10.40 million, total current assets were $14.84 million and current liabilities were $4.44 million. Total assets were $15.85 million. The balance sheet reports no conventional borrowings; it does include lease obligations and current warrant, investment-option and derivative liabilities. No revenue or profit margin is applicable given the absence of revenue and continuing losses.
Material changes and operating developments
- Compared with Q1 2022, operating expenses rose modestly. General and administrative costs were broadly flat, while R&D increased about 2%. Net loss increased by about $0.15 million.
- Operating cash use rose about $0.59 million year over year. Q1 2023 had no financing proceeds, compared with $9.40 million of financing cash inflows in Q1 2022.
- In March, Enveric established an Australian subsidiary and selected Avance Clinical to manage a planned Phase 1 study of EB-373. The contract is approximately AUD 3.0 million (about $2.0 million at quarter-end); the filing says approximately $1.1 million was payable to Avance and recorded in accounts payable at March 31.
- In May 2023, the Akos preferred investor exercised its put right, requiring redemption of all Akos Series A preferred stock for approximately $1.05 million, including accrued dividends. Enveric guaranteed payment, due within 20 days after receipt of the exercise notice. The planned Akos spin-off had not occurred.
Outlook, risks and unusual items
- Going concern: Management concluded substantial doubt exists about Enveric’s ability to continue as a going concern for one year after issuance. It states that cash and working capital are insufficient for operating needs over the next 12 months. Plans include reducing spending, managing cash, advancing programs and seeking additional financing or collaborations; financing may not be available on acceptable terms or at all.
- Cost reduction: In May, the company announced a reduction of approximately 35% of full-time employees and termination of seven consultants working on the Akos spin-off. It expects about $500,000 in severance and benefit costs, primarily in Q2 2023, and expected substantial completion by quarter-end. Savings and timing are uncertain, and the filing warns of potential disruption and additional costs.
- Development and regulatory risk: Candidates remain early-stage, and clinical, regulatory, safety, efficacy, financing, intellectual-property, manufacturing and collaboration outcomes are uncertain. The planned EB-373 Phase 1 study is not evidence of clinical efficacy; the candidate was described as being in preclinical development.
- Accounting and controls: Fair-value gains on warrant, investment-option and derivative liabilities contributed $183,000 of other income in Q1 and are based on Level 3 estimates. Management reported continuing material weaknesses in internal control over financial reporting and concluded disclosure controls were not effective at March 31, 2023.
- The filing provides no formal financial guidance. It notes inflation-related cost and labor risks and foreign-exchange exposure to Canadian and Australian currencies.
Key facts for investors to verify
- Available cash, operating burn and management’s financing plans against the explicit 12-month funding shortfall and going-concern warning.
- Whether Enveric paid the approximately $1.05 million Akos redemption obligation on time, and the resulting effect on cash and the spin-off plan.
- Execution, timing and actual costs of the workforce reduction, including whether projected savings can sustain pipeline work.
- EB-373 clinical-readiness milestones, the Avance contract’s remaining payment obligations and any change in planned study timing or scope.
- Progress in remediating internal-control material weaknesses and any subsequent changes to outstanding shares or potential dilution.